CIVCO Radiotherapy, a provider of patient-centric radiotherapy solutions, announced their partnership with POLL Medical, as the exclusive global provider of GrayDuck Stents™ for custom oral positioning and immobilization of the tongue.
"This collaboration aligns with our mission to improve outcomes for patients worldwide." said John Steffen, Director of Product Management at CIVCO Radiotherapy. "The innovative GrayDuck Stent is currently the only custom-fitted bite block system that can position the tongue in one of several positions; laterally (left or right), depressing (downward) or a combination thereof. This unique device improves patient treatment and outcomes by protecting the tongue, taste buds and salivary glands during radiotherapy.
"The GrayDuck Stent offers patients undergoing radiotherapy for head and neck cancers a safer treatment experience, by sparing the tongue from unnecessary damage. No other device on the market offers the ability to customize the positioning of the tongue away from the radiation field" stated Adrian Polliack, CEO of POLL Medical. "POLL Medical is thrilled to partner with CIVCO Radiotherapy, whose global reach will afford many radiotherapy patients around the world access to the GrayDuck Stent."
GrayDuck Stents is CE Marked and available through CIVCO's global distribution channels. The device is currently pending FDA 510(k) clearance.Back To Top
CIVCO, POLL Medical to offer GrayDuck tongue-displacing and immobilization oral stents . Appl Rad Oncol.